Clarity Pharmaceuticals Ltd has released a press release.
Recruitment target achieved for Phase II SAR-Bombesin trial
Filed with ASX ·
6ix hasn’t read this filing yet.
Clarity Pharmaceuticals Ltd. on 6ix
Story so far
Earlier from Clarity Pharmaceuticals
- Presentation for Wilsons Drug and Device Conference
- First patient treated with Cu-67 SAR-Bombesin
- Company Presentation E&P Small Cap Healthcare Conference
- BOP preliminary trial results presented at EANM 2023
- First neuroblastoma participant treated in highest cohort
Later from Clarity Pharmaceuticals
- Bell Potter Healthcare Conference Presentation
- SECuRE theranostic prostate cancer trial progresses
- undetectable PSA level with Cu-67 SAR-bisPSMA
- Phase III CLARIFY trial in prostate cancer commences
- Recruitment closes for a diagnostic Phase II trial in NETs
Follow Clarity Pharmaceuticals into a list and get an email when it puts out news.
Follow Clarity Pharmaceuticals